{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T23:54:46Z","timestamp":1746489286873,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10620-021-07257-y","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T02:24:38Z","timestamp":1633659878000},"page":"4033-4042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["De Novo Ostomy Placement Is Associated with Increased Outpatient Opioid Use In Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6673-4096","authenticated-orcid":false,"given":"Loren G.","family":"Rabinowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley M.","family":"Zylberberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie Lauren","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn","family":"Chesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"7257_CR1","unstructured":"CDC. Opioid Overdose: Drug Overdose Deaths. https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html (2018)."},{"key":"7257_CR2","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","volume":"65","author":"JM Dahlhamer","year":"2016","unstructured":"Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged >\/=18 years\u2014United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65:1166\u20131169. https:\/\/doi.org\/10.15585\/mmwr.mm6542a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7257_CR3","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/ajg.2014.230","volume":"109","author":"LE Targownik","year":"2014","unstructured":"Targownik LE, Nugent Z, Singh H, Bugden S, Bernstein CN. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol 2014;109:1613\u20131620. https:\/\/doi.org\/10.1038\/ajg.2014.230.","journal-title":"Am J Gastroenterol"},{"key":"7257_CR4","doi-asserted-by":"publisher","first-page":"e0156666","DOI":"10.1371\/journal.pone.0156666","volume":"11","author":"J Zeitz","year":"2016","unstructured":"Zeitz J et al. Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS ONE 2016;11:e0156666. https:\/\/doi.org\/10.1371\/journal.pone.0156666.","journal-title":"PLoS ONE"},{"key":"7257_CR5","doi-asserted-by":"crossref","unstructured":"In Diagnostic and Statistical Manual of Mental Disorders (ed American Psychiatric Association) (2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"7257_CR6","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.1136\/bmj.h6905","volume":"351","author":"M McCarthy","year":"2015","unstructured":"McCarthy M. Opioids should be last resort to treat chronic pain, says draft CDC guideline. BMJ (Clin Res Ed) 2015;351:6905. https:\/\/doi.org\/10.1136\/bmj.h6905.","journal-title":"BMJ (Clin Res Ed)"},{"key":"7257_CR7","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJMp1515917","volume":"374","author":"TR Frieden","year":"2016","unstructured":"Frieden TR, Houry D. Reducing the risks of relief-the CDC opioid-prescribing guideline. N Engl J Med 2016;374:1501\u20131504. https:\/\/doi.org\/10.1056\/NEJMp1515917.","journal-title":"N Engl J Med"},{"key":"7257_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/apt.15023","volume":"49","author":"M Noureldin","year":"2019","unstructured":"Noureldin M et al. Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. Aliment Pharmacol Ther 2019;49:74\u201383. https:\/\/doi.org\/10.1111\/apt.15023.","journal-title":"Aliment Pharmacol Ther"},{"key":"7257_CR9","doi-asserted-by":"publisher","unstructured":"Dalal RS et al. Exposure to intravenous opioids is associated with future exposure to opioids in hospitalized patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18:2269\u20132278 e2263. https:\/\/doi.org\/10.1016\/j.cgh.2019.12.024.","DOI":"10.1016\/j.cgh.2019.12.024"},{"key":"7257_CR10","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/ecco-jcc\/jjy062","volume":"12","author":"S Cohen-Mekelburg","year":"2018","unstructured":"Cohen-Mekelburg S et al. The impact of opioid epidemic trends on hospitalised inflammatory bowel disease patients. J Crohn\u2019s Colitis 2018;12:1030\u20131035. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy062.","journal-title":"J Crohn's Colitis"},{"key":"7257_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409\u20131422. https:\/\/doi.org\/10.1038\/ajg.2012.218.","journal-title":"Am J Gastroenterol"},{"key":"7257_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR et al. Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621\u2013630. https:\/\/doi.org\/10.1016\/j.cgh.2006.03.002.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7257_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ibd.21806","volume":"18","author":"MD Long","year":"2012","unstructured":"Long MD, Barnes EL, Herfarth HH, Drossman DA. Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm Bowel Dis 2012;18:869\u2013876. https:\/\/doi.org\/10.1002\/ibd.21806.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl","key":"7257_CR14","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1097\/MCG.0b013e31821fbd82","volume":"45","author":"GK Makharia","year":"2011","unstructured":"Makharia GK. Understanding and treating abdominal pain and spasms in organic gastrointestinal diseases: inflammatory bowel disease and biliary diseases. J Clin Gastroenterol 2011;45:S89-93. https:\/\/doi.org\/10.1097\/MCG.0b013e31821fbd82.","journal-title":"J Clin Gastroenterol"},{"key":"7257_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/gut.2005.080887","volume":"55","author":"D Philippe","year":"2006","unstructured":"Philippe D et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut 2006;55:815\u2013823. https:\/\/doi.org\/10.1136\/gut.2005.080887.","journal-title":"Gut"},{"key":"7257_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrgastro.2017.141","volume":"15","author":"E Szigethy","year":"2018","unstructured":"Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Nat Rev Gastroenterol Hepatol 2018;15:168\u2013180. https:\/\/doi.org\/10.1038\/nrgastro.2017.141.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7257_CR17","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1097\/MIB.0000000000000170","volume":"20","author":"A Srinath","year":"2014","unstructured":"Srinath A, Young E, Szigethy E. Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside. Inflamm Bowel Dis 2014;20:2433\u20132449. https:\/\/doi.org\/10.1097\/MIB.0000000000000170.","journal-title":"Inflamm Bowel Dis"},{"key":"7257_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park KT et al. The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & colitis foundation. Inflamm Bowel Dis 2020;26:1\u201310. https:\/\/doi.org\/10.1093\/ibd\/izz104.","journal-title":"Inflamm Bowel Dis"},{"key":"7257_CR19","doi-asserted-by":"publisher","unstructured":"Ramos-Rivers C et al. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:986\u2013994 e981. https:\/\/doi.org\/10.1016\/j.cgh.2013.11.015","DOI":"10.1016\/j.cgh.2013.11.015"},{"key":"7257_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/ajg.2012.343","volume":"108","author":"N Hazratjee","year":"2013","unstructured":"Hazratjee N, Agito M, Lopez R, Lashner B, Rizk MK. Hospital readmissions in patients with inflammatory bowel disease. Am J. Gastroenterol. 2013;108:1024\u20131032. https:\/\/doi.org\/10.1038\/ajg.2012.343.","journal-title":"Am J. Gastroenterol."},{"key":"7257_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M18-2864","volume":"171","author":"JM Donohue","year":"2019","unstructured":"Donohue JM et al. Patterns of opioid administration among opioid-naive inpatients and associations with postdischarge opioid use: a cohort study. Ann Intern Med 2019;171:81\u201390. https:\/\/doi.org\/10.7326\/M18-2864.","journal-title":"Ann Intern Med"},{"key":"7257_CR22","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/MIB.0000000000001084","volume":"23","author":"N Narula","year":"2017","unstructured":"Narula N, Borges L, Steinhart AH, Colombel JF. Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011. Inflamm Bowel Dis 2017;23:868\u2013874. https:\/\/doi.org\/10.1097\/MIB.0000000000001084.","journal-title":"Inflamm Bowel Dis"},{"key":"7257_CR23","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/ecco-jcc\/jjaa059","volume":"14","author":"K Sultan","year":"2020","unstructured":"Sultan K, Swaminath A. From bad to worse: the relationship between opioid use and inflammatory bowel disease. J Crohn\u2019s Colitis 2020;14:1188\u20131189. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa059.","journal-title":"J Crohn's Colitis"},{"key":"7257_CR24","doi-asserted-by":"publisher","unstructured":"Burr NE, Smith C, West R, Hull MA, Subramanian V. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin Gastroenterol Hepatol. 2018;16:534\u2013541 e536. https:\/\/doi.org\/10.1016\/j.cgh.2017.10.022.","DOI":"10.1016\/j.cgh.2017.10.022"},{"key":"7257_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.07.020","author":"T Chhibba","year":"2020","unstructured":"Chhibba T et al. Frequency of opioid prescription at emergency department discharge in patients with inflammatory bowel disease: a nationwide analysis. Clin Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.cgh.2020.07.020.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7257_CR26","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/MIB.0000000000001087","volume":"23","author":"NJ Pauly","year":"2017","unstructured":"Pauly NJ et al. Predictors of chronic opioid use in newly diagnosed Crohn\u2019s disease. Inflamm Bowel Dis 2017;23:1004\u20131010. https:\/\/doi.org\/10.1097\/MIB.0000000000001087.","journal-title":"Inflamm Bowel Dis"},{"key":"7257_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/01.psy.0000106907.24881.f2","volume":"66","author":"C Mittermaier","year":"2004","unstructured":"Mittermaier C et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004;66:79\u201384. https:\/\/doi.org\/10.1097\/01.psy.0000106907.24881.f2.","journal-title":"Psychosom Med"},{"key":"7257_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/jgh3.12236","volume":"4","author":"A Mikocka-Walus","year":"2020","unstructured":"Mikocka-Walus A et al. Psychological distress is highly prevalent in inflammatory bowel disease: a survey of psychological needs and attitudes. JGH Open 2020;4:166\u2013171. https:\/\/doi.org\/10.1002\/jgh3.12236.","journal-title":"JGH Open"},{"key":"7257_CR29","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/ibd\/izz100","volume":"25","author":"K Alley","year":"2019","unstructured":"Alley K, Singla A, Afzali A. Opioid use is associated with higher health care costs and emergency encounters in inflammatory bowel disease. Inflamm Bowel Dis 2019;25:1990\u20131995. https:\/\/doi.org\/10.1093\/ibd\/izz100.","journal-title":"Inflamm Bowel Dis"},{"key":"7257_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MEG.0000000000001615","volume":"32","author":"L Sweeney","year":"2020","unstructured":"Sweeney L, Moss-Morris R, Czuber-Dochan W, Murrells T, Norton C. Developing a better biopsychosocial understanding of pain in inflammatory bowel disease: a cross-sectional study. Eur J Gastroenterol Hepatol 2020;32:335\u2013344. https:\/\/doi.org\/10.1097\/MEG.0000000000001615.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"7257_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/apt.14493","volume":"47","author":"L Sweeney","year":"2018","unstructured":"Sweeney L et al. Systematic review: psychosocial factors associated with pain in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:715\u2013729. https:\/\/doi.org\/10.1111\/apt.14493.","journal-title":"Aliment Pharmacol Ther"},{"key":"7257_CR32","unstructured":"NYSDOH. I-STOP\/PMP\u2014Internet System for Tracking Over-Prescribing\u2014Prescription Monitoring Program. https:\/\/www.health.ny.gov\/professionals\/narcotic\/prescription_monitoring\/. (2013)."},{"key":"7257_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1521-0391.2013.00319.x","volume":"22","author":"KM Lawson","year":"2013","unstructured":"Lawson KM, Back SE, Hartwell KJ, Moran-Santa Maria M, Brady KT. A comparison of trauma profiles among individuals with prescription opioid, nicotine, or cocaine dependence. Am J Addict 2013;22:127\u2013131. https:\/\/doi.org\/10.1111\/j.1521-0391.2013.00319.x.","journal-title":"Am J Addict"},{"key":"7257_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1465-3362.2011.00314.x","volume":"31","author":"G Dore","year":"2012","unstructured":"Dore G, Mills K, Murray R, Teesson M, Farrugia P. Post-traumatic stress disorder, depression and suicidality in inpatients with substance use disorders. Drug Alcohol Rev 2012;31:294\u2013302. https:\/\/doi.org\/10.1111\/j.1465-3362.2011.00314.x.","journal-title":"Drug Alcohol Rev"},{"key":"7257_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107959","volume":"210","author":"E Takemoto","year":"2020","unstructured":"Takemoto E, Brackbill R, Martins S, Farfel M, Jacobson M. Post-traumatic stress disorder and risk of prescription opioid use, over-use, and misuse among World Trade Center Health Registry enrollees, 2015\u20132016. Drug Alcohol Depend 2020;210:107959. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107959.","journal-title":"Drug Alcohol Depend"},{"key":"7257_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/ecco-jcc\/jjz198","volume":"14","author":"P Charilaou","year":"2020","unstructured":"Charilaou P et al. Opioid use disorder increases 30-day readmission risk in inflammatory bowel disease hospitalizations: a nationwide matched analysis. J Crohn\u2019s Colitis 2020;14:636\u2013645. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz198.","journal-title":"J Crohn's Colitis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-07257-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:27:26Z","timestamp":1657906046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-07257-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["7257"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-07257-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"22 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LR has no conflicts of interest and nothing to disclose. HZ has no conflicts of interest and nothing to disclose. JY has no conflicts of interest and nothing to disclose. SG has no conflicts of interest and nothing to disclose. JC has no conflicts of interest and nothing to disclose. JJ has no conflicts of interest and nothing to disclose. LH has no conflicts of interest and nothing to disclose. MD has the following disclosures to report: Consultant Abbvie, Arena, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus Biosciences, Takeda, Target RWE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}